Doig P A, Purbrick K A, Hare J E, McKeown D B
Boehringer Ingelheim Vetmedica, Burlington, Ontario, Canada.
Can Vet J. 2000 Apr;41(4):296-300.
A clinical trial was conducted to evaluate the safety and efficacy of the nonsteroidal anti-inflammatory drug meloxicam in dogs with chronic osteoarthritis. Forty clinical cases were enrolled in the 2-phase study. Phase 1 compared therapeutic efficacy and tolerance of meloxicam or placebo for 1 week. Phase 2 involved a 4-week evaluation of the drug's clinical efficacy and tolerance. Clinical efficacy was evaluated by using a scoring system that assessed specific lameness, general stiffness, painful rise, exercise intolerance, and behavior. Evaluations demonstrated significant reductions (P < 0.05) in clinical signs of osteoarthritis following 4 weeks of drug therapy. Side effects were minimal in extent and duration. The drug was accepted without problems in the majority of cases. The findings of this investigation suggest that the efficacy, tolerance, and formulation of meloxicam oral suspension make it well suited for the treatment of chronic osteoarthritis in the dog.
进行了一项临床试验，以评估非甾体抗炎药美洛昔康对患有慢性骨关节炎的犬的安全性和有效性。40例临床病例纳入了该2期研究。第1阶段比较了美洛昔康或安慰剂1周的治疗效果和耐受性。第2阶段涉及对该药物临床疗效和耐受性的4周评估。通过使用评估特定跛行、全身僵硬、疼痛性起身、运动不耐受和行为的评分系统来评估临床疗效。评估表明，药物治疗4周后骨关节炎的临床症状显著减轻（P<0.05）。副作用在程度和持续时间上最小。在大多数病例中，该药物的接受情况没有问题。这项研究的结果表明，美洛昔康口服混悬液的疗效、耐受性和剂型使其非常适合治疗犬的慢性骨关节炎。
